Join to view full profile
NKGen Biotech3001 Daimler StSanta Ana, CA 92705
Phone+1 310-310-1992
Dr. Song is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Paul Song, MD, is a radiation oncologist based in Santa Ana, CA. He completed his medical education at George Washington University School of Medicine and his residency in Radiation Oncology at the University of Chicago/University of Illinois, following an internship at Cooperman Barnabas Medical Center. Currently, he serves as Chairman/CEO of NKGen Biotech, having previously been the CEO at FuseBio Therapeutics. His published works include studies on gene and cell therapy for sarcomas, Alzheimer's disease treatments, and management of radiation-induced mucosal necrosis, with several of his publications being cited multiple times. Additionally, he has been involved in clinical trials focusing on the safety of SNK01 in treating cancer patients.
Education & Training
University of Chicago/University of Illinois College of Medicine at ChicagoResidency, Radiation Oncology, 1992 - 1996
Cooperman Barnabas Medical CenterInternship, Transitional Year, 1991 - 1992
George Washington University School of Medicine and Health SciencesClass of 1991
Certifications & Licensure
CA State Medical License 2007 - 2028
IL State Medical License 1992 - 2014
NV State Medical License 2005 - 2009
VA State Medical License 1996 - 2008
SC State Medical License 1995 - 1996
Clinical Trials
- Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Start of enrollment: 2019 Jul 15
Publications & Presentations
PubMed
- 1 citationsGene and Cell Therapy for Sarcomas: A Review.Sant P Chawla, Skyler S Pang, Darshit Jain, Samantha Jeffrey, Neal S Chawla
Cancers. 2025-03-27 - 6 citationsTreatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study.Clemente Humberto Zúñiga, Blanca Isaura Acosta, Rufino Menchaca, Cesar A Amescua, Sean Hong
Alzheimer's Research & Therapy. 2025-02-12 - 4 citationsManagement of radiation-induced mucosal necrosis with photobiomodulation therapy.Joel B. Epstein, Paul Y. Song, Allen S. Ho, Babak Larian, Arash Asher
Supportive Care in Cancer. 2018-05-04
Press Mentions
NKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting TherapyJuly 10th, 2025- NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use ProgramFebruary 21st, 2025
- NKGen's Troculeucel Therapy Demonstrates Stability and Cognitive Improvement in AD TrialFebruary 13th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
